Work

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.2566

Authors: Patricia LoRusso, Geoffrey Shapiro, Shuchi Sumant Pandya, Eunice Lee Kwak, Cheryl Jones, Marcia Belvin, Luna C. Musib, Alex de Crespigny, Meghan McKenzie, Mary R. Gates, Iris Tan-Chi Chan, Johanna C. Bendell

Institutions: The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Harvard University, Massachusetts General Hospital, Genentech, Sarah Cannon

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602871482

Cites:

Cited by: 48

Related to: 10